Addex Therapeutics Ltd (ADXN) stock analysis

Healthcare · Biotechnology

From the 20-F filed 2026-05-15

How it makes money

It earns revenue by securing research grants or partnering drug programs with larger pharmaceutical companies that fund development in exchange for future rights.

As a clinical-stage company with no products on the market, it relies on external funding. It earns through research collaborations, such as its agreement with Indivior PLC, or by receiving grants from government and non-governmental organizations. Profitability depends on its ability to sign new partnership agreements and secure research subsidies to offset its high development costs.

What protects it: the moat

It relies on intellectual property rights for its drug candidates, though it lacks market-proven commercial exclusivity.

It attempts to protect its future earnings through exclusive licenses and proprietary technology covering its small molecule drug candidates. However, it explicitly notes that it is a development-stage company with no products on the market, meaning its competitive advantage remains theoretical until regulatory and clinical hurdles are cleared.

What growth costs

It must continuously burn cash for clinical trials, regulatory compliance, and R&D to advance its drug pipeline toward potential commercialization.

Growth costs are defined by the intensive financial requirements of clinical testing and regulatory approvals. It must fund internal development activities or expand operations, and it faces the constant need for additional capital to sustain these programs. It also cites the potential cost of developing internal sales and marketing capabilities if it chooses to commercialize drugs independently.

What could damage it

If a partner terminates a development agreement, it loses the funding and specialized resources required to advance that specific drug candidate.

Because the company lacks independent commercial infrastructure and relies on third parties for development, the withdrawal of a partner directly impairs its ability to progress a program. When a partner like Janssen terminates an agreement, the company is left with the full financial and operational burden of a program that has already failed to meet its primary clinical endpoints.

About Addex Therapeutics Ltd

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Other companies in Biotechnology